3 Small-Cap ‘Strong Buy’ Stocks with Big Upside in 2026, According to Analysts

FomoAnxiety · 2026-03-02T17:15:56+00:00

Small-cap stocks like Diversified Energy Company, AtriCure, and Innoviva are gaining attention for their strong fundamentals and growth potential, each having the possibility of over 50% upside from current stock levels.

FomoAnxiety

2026-03-02 17:15:56

Abstract generation in progress

Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Diversified Energy Company DEC +2.47% ▲ , Atricure ATRC -1.82% ▼ , and Innoviva INVA -0.04% ▼ as companies with solid fundamentals and strong growth potential, each with the possibility of more than 50% upside from current levels.

Claim 50% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

Let’s dive into the details.

Is Diversified Energy a Good Stock to Buy?

DEC is an oil and gas producer operating in the Appalachian Basin and Central U.S., focused on efficient energy production. Year-to-date, DEC stock is down by 3%.

Looking ahead, Wall Street is bullish on DEC with a Strong Buy rating backed by six Buys assigned in the last three months. Meanwhile, Diversified Energy Company’s average stock price target of $21.41 suggests over 50% upside from current levels.

Is AtriCure Stock a Good Buy?

AtriCure, Inc. is a medical device company specializing in innovative surgical solutions for treating atrial fibrillation and related heart rhythm disorders. Their products focus on minimally invasive procedures that improve patient outcomes and reduce recovery time. ATRC stock has fallen 22% year-to-date.

For 2026, analysts have rated the stock as a Strong Buy backed by six Buys and two Holds assigned in the last three months. Meanwhile, AtriCure’s average stock price target of $49.29 suggests a potential upside of 61% from current levels.

Is Innoviva a Good Stock to Buy?

Innoviva is a biotech company that develops and commercializes respiratory and other specialty therapies, focusing on partnerships and royalty-based revenue streams. Year-to-date, INVA stock is up 15%.

Looking ahead, Wall Street is bullish on INVA with a Strong Buy rating backed by four Buys assigned in the last three months. Meanwhile, Innoviva’s average stock price target of $37.0 suggests over 60% upside from current levels.

Disclaimer & DisclosureReport an Issue

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes